(2S,5R,6R)-6-[6-[5-[(3aS,4S,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]hexanoylamino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (2S,5R,6R)-6-[6-[5-[(3aS,4S,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]hexanoylamino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
• 化学式: C₂₄H₃₇N₅O₆S₂
• 分子量: 555.7
• InChiKey: BULDNFRWBUEADH-BVUUIFSISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  37
• 可旋转键数：
  13
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.79
• 拓扑面积：
  208
• 氢给体数：
  5
• 氢受体数：
  8

文献信息

• DRUG CONJUGATES AND METHODS OF DESIGNING THE SAME
  申请人：Brenner, Sydney

  公开号：EP1212096A2

  公开（公告）日：2002-06-12
• [EN] DRUG CONJUGATES AND METHODS OF DESIGNING THE SAME<br/>[FR] CONJUGUES DE MEDICAMENTS ET LEURS PROCEDES DE PREPARATION
  申请人：BRENNER SYDNEY

  公开号：WO2001013958A2

  公开（公告）日：2001-03-01

  The invention relates to drug conjugates and methods of their design. One embodiment of the invention is directed to a method of designing vector-linker-pharmacophore ('VLP') conjugates that is generally applicable to a wide variety of vectors, linkers, and pharmacophores. The invention also encompasses a method of improving the delivery of a pharmacophore to a patient, as well as a method of improving the therapeutic efficacy of a pharmacophore and a method of decreasing the toxicity of a pharmacophore. A method of increasing the concentration of a pharmacophore in a cell is further encompassed by the invention.